Aoyi Technologies Secures Nearly RMB 1 Billion in Series B+ Financing to Accelerate Global Commercialization of Brain-Computer Interface and Robotic Products

VCBeat learned第一时间 that recently, focusing on the brain-computer interface and robotics fields,UpOYMotion Technology Co., Ltd (Abbreviation: OYMotion)Completed nearly 100 million yuan in B+ round financing. This round of financing was led byLed by Zhuhai Huafa Group Co.,Ltd., with participation from VCBeat and Hony CapitalFollow-up Investment,Krypton CapitalServed as the financial advisor to OYMotion in this transaction.

The funds from this round of financing will help OYMotion build a high-standard production system, completing the last piece of the company's commercial blueprint. The construction of this production line aims to strengthen the company's core R&D and manufacturing capabilities, increase production capacity, improve delivery performance, and further accelerate the commercial rollout of multiple products in global markets.

In 2015, OYMotion was founded in Zhangjiang High-Tech Park, Shanghai. Since its establishment, the team has been focusing on the intersection of two core technologies: brain science and robotics. It has successfully built a research and development platform that integrates neural interface, robotics, and artificial intelligence technologies, and launched several products with both high technical barriers and cost-effectiveness. These products have gained widespread recognition in domestic and overseas markets. OYMotion is a leading high-tech enterprise in China that possesses the two underlying technologies of brain-computer interface and robotics.

In the field of brain science, OYMotion, based on its self-developed brain/muscle-computer interface technology, has built a medical-grade neuro-interaction software and hardware integrated infrastructure platform, which has obtained more than 80 patents so far. Its product line includes the OB series of brain-computer interfaces, the OHand™ series of intelligent bionic hands, the ORF series of neuro-rehabilitation exoskeletons, and more. Since its launch in 2020, the OHand™ intelligent bionic hand has quickly captured the market share of imported products with its cutting-edge technical performance and ultra-high cost-effectiveness.

In 2023, OHand™ bionic hand successively obtained FDA/CE certifications and acquired the U.S. PDAC commercial insurance payment code last year. It has taken the lead in launching overseas commercialization in multiple countries and regions worldwide, including the United States, the Middle East, Russia, Ukraine, and India. OYMotion's bionic hand has become a hallmark of Chinese innovation.

OYMotion's neurorehabilitation ORF series products have also been approved to enter the special review channel for innovative medical devices in Shanghai in 2024. The product is mainly aimed at motor function disorders caused by functional diseases such as stroke, brain injury, and cerebral palsy. Through OYMotion's brain-muscle-machine three-level rehabilitation training system, it accelerates patient benefits and significantly improves clinical rehabilitation outcomes.

In addition, the company's non-invasive brain-computer interface products have been sold to multiple overseas customers. In the future, the company will further increase its investment in brain-computer interface products.

In the field of embodied robotics, OYMotion has taken the lead in launching the ROhand series of dexterous hand products, leveraging years of technical accumulation in this area. With its first-mover advantage in technology, OYMotion has already established partnerships with several top embodied robotics companies in China and stands as a leading player in the first tier of the domestic dexterous hand market.

OYMotion's ROHand is a highly sensitive robotic end-effector. The ROH-A001 model features 6 active degrees of freedom and 5 passive degrees of freedom, totaling 11 DOF. In terms of appearance and structural design, OYMotion has chosen dimensions and proportions closest to the human hand, perfectly interpreting the significance of ergonomics and granting ROHand human-like flexibility and precise operational capabilities. Additionally, each finger of the ROHand can bear a maximum load of 10KG, with the entire hand capable of handling loads up to 30KG, covering multiple complex usage scenarios in the field of embodied robotics.

Brain science is hailed as the ultimate frontier of human scientific research, and embodied robots are also an important carrier of new quality productivity. OYMotion possesses two core underlying technologies: brain-computer interface and embodied dexterous hands, which are expected to benefit from the rapid growth dividends of a billion-dollar market. Meanwhile, as a company with global genes, OYMotion places great emphasis on the construction of overseas channels.

The company has established comprehensive sales channels and after-sales systems in many countries and regions around the world. As more products come to market, the company will further increase its overseas sales share. This round of financing will also help the company expand new production capacity and teams, further meeting the rapid growth in commercialization.

OYMotion Founder Hua Liang NiExpressed: Thanks to all new investors for their trust and recognition, and also thanks to all old shareholders for their long-term support. Brain-computer interface and embodied robots are important technological inflection points that will open the next era. Since its establishment, OYMotion has been focusing on the intersection of these two technologies and has developed multiple technology-based products with clear market demand, clear user benefits, and clear commercial prospects. After the completion of this round of financing, OYMotion will further accelerate capacity building and expand its R&D and commercial capabilities, growing as soon as possible into a global enterprise with tremendous positive influence.

Zhuhai Huafa Group Co.,Ltd.Representation: Directions such as brain-computer interfaces and embodied intelligence in high-end manufacturing have always been key focus areas for Zhuhai Huafa Group Co., Ltd. OYMotion not only possesses strong technical capabilities but also demonstrates significant advantages in supply chain integration and commercial execution. The company’s bionic hand and dexterous hand products have gained widespread recognition from domestic and international downstream customers, with sales increasing rapidly. Additionally, the company has made rapid progress in the field of neurorehabilitation. Zhuhai Huafa Group is willing to collaborate with outstanding enterprises to promote the development of China's high-end manufacturing in the life and health sector.

Grand HuitoneRepresentation: Grand Capital is a professional industrial background investment institution focusing on the field of technological innovation. Brain-computer interface and robotics are key sectors where Grand Capital has made significant investments. OYMotion, as an innovative enterprise in the brain-computer interaction field, boasts high product technical content and broad market prospects. With the advancement of technology, the demand for limb rehabilitation and functional replacement is increasing. Relying on advanced human-computer interaction technology, OYMotion is expected to fill the market gap and meet the needs of numerous patients seeking a high-quality life. Its R&D team is professional and dynamic, continuously driving product iteration and upgrades, injecting strong momentum into the company's development. It is hoped that in the future, Grand Capital, with its industrial advantages in the hard technology sector, will collaborate with OYMotion for common development.

Feng Zhihua, President of Heying CapitalRepresentation: As a key area of focus for Harvest Capital, brain-computer interface development is tied to industrial funds to support high-growth technology companies. After years of dedicated efforts, OYMotion has leveraged its robust R&D capabilities and engineering solutions to create premium flagship products such as intelligent bionic hands and dexterous hands for industrial applications, along with a future product portfolio for in-hospital and out-of-hospital rehabilitation. These achievements have led to significant progress, positioning OYMotion as one of the first companies in China’s brain-computer interface industry to successfully commercialize. The company shows great promise for the future. With deep industry insights and an extensive ecosystem in the brain-computer interface sector, Harvest Capital continues to support OYMotion's growth. We also look forward to closer collaboration between OYMotion and Harvest Capital's strategic partners, including the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Symbiosis and the Tianjin Brain-Computer Interface Industry Pilot Zone.

Ding Huanxing, Founder of Krypton CapitalRepresentation: Brain science and robotics are currently industries with extremely high development potential. OYMotion possesses industry-leading technical capabilities. Under the leadership of the founding team, the company, with strong execution ability, closely aligns with commercial demands and has built a product portfolio with high barriers in terms of technical performance and supply chain costs. Despite the downturn in the economic environment, it has still achieved rapid sales growth, which is a key factor for the company to successfully secure financing during the capital winter.

Zhuhai Huafa Group Co., Ltd. was established in 1980, the same year as the Zhuhai Special Economic Zone. It is the largest comprehensive state-owned enterprise group in Zhuhai and a nationally renowned leading company. The group currently controls seven listed companies and two enterprises listed on the New Third Board, and has built five "AAA" credit entities. In 2024, it ranked 152nd in the "Top 500 Chinese Enterprises." By the end of 2024, the group's total assets exceeded 720 billion yuan. In the field of industrial investment, Huafa Group focuses on key sectors such as the digital economy, artificial intelligence, robotics, low-altitude economy, healthcare, and new energy. Its subsidiary, Huafa Technology, ranks 8th among the top 100 industrial investment companies in China, and Huajin Capital has repeatedly been listed on the Zero2IPO "Top 50 Private Equity Investment Institutions in China."

Beijing Grand Innovation Engineering Technology Research Institute is a professional investment institution dedicated to growth-stage private equity investment. It relies on the semiconductor and digital intelligence全产业链 resources of Rongxin Industry Alliance and the new Ziguang system, focusing on core technologies in the泛半导体 field and related digital intelligence, new energy, and healthcare硬科技 ecosystem areas. With the mission of "Building a grand innovation ecosystem, channeling growth value," it aims to discover and empower top-tier frontier technologies and China-produced alternatives in硬科技 industries under the backdrop of technological innovation driving China's new round of economic growth. By using innovative enterprise equity investment as a link, it provides specialized industrial resource allocation and services for technology innovation companies, innovative cities, and market capital, with the goal of cultivating future leaders in细分 industries and sharing corporate and industry growth value with partners.

As a shareholder of Tianjin Haihe Industrial Fund Management Co., Ltd., the government-guided fund of Tianjin, Harvest Capital holds a seat on the board of directors. On this basis, it has established multiple industrial funds, including Zhongke Haihe Biomedical Industry Fund, Brain-Machine Harvest Haihe Haitai Venture Capital Fund, and Huailai Big Data Fund. With the core concept of "Focus, Professionalism, Cooperation, and Win-Win," adhering to the principle of "Discovering and Supporting Outstanding Chinese Technology Enterprises and Growing Together with Them," it focuses on investment opportunities in fields such as brain science and brain-inspired intelligence, biomedicine, and synthetic biology.

ShengKe Agent Capital is a new financial advisory firm focused on the healthcare and life sciences sectors. The founder has over a decade of experience in pharmaceutical R&D, investment, and financial advisory, known for strong execution capabilities and professionalism. Even during the capital winter, the company has helped multiple firms complete financing totaling hundreds of millions of yuan.